In this episode of Targeted Talks, Alfred L. Garfall, discusses the phase 2 BMT CTN 1902 trial of idecabtagene vicleucel in ...
Dealbreaker on MSN3d
Bristol Myers Squibb Buys Out Cancer Cell Therapy Partner 2seventy Bio In $286M DealMultiple myeloma cell therapy Abecma is the lone remaining asset of 2seventy Bio, which spun out from Bluebird Bio ...
An elderly patient who was initially suspected of having antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) was instead diagnosed with multiple myeloma, according to a case report ...
Bristol-Myers Squibb acquires 2seventy bio for $286M, marking the end of a once-promising biotech. Check out if this is a ...
During a Case-Based Roundtable® event, Robert Z. Orlowski, MD, PhD, discussed the case of a patient who had progression of ...
A multiple myeloma treatment offers hope, but has a high cost. A Houston trial aims to make this life-saving therapy ...
We believe Genmab is in solid financial health. At the end of 2024, Genmab held DKK 9.9 billion in cash and cash equivalents. After turning profitable in 2013, the company has steadily increased its ...
KSQ Therapeutics, Inc. (KSQ), a clinical-stage biotechnology company developing novel treatments for solid tumors, including ...
When you think about multiple personalities, what is the first thing that comes to your mind? For many, it is a disturbing picture from a Hollywood film about a deranged and sociopathic murderer.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback